AstraZeneca has drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions. The Anglo-Swedish drugmaker began discussing the idea with bankers several months ago and is among a growing number of multinational companies now considering that option, according to three people familiar with the talks.
阿斯利康(AstraZeneca)已拟定计划，分拆其manbetx3.0 业务并在香港单独上市，以规避日益加剧的地缘政治紧张局势影响。
您已阅读9%（451字），剩余91%（4412字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。